TROG 03.01 – Oesophagus
A randomised phase III study in advanced oesophageal carcinoma to compare dysphagia in patients treated with radiotherapy versus chemo-radiotherapy.
The TROG 03.01 trial was the largest randomised phase three trial in advanced oesophageal cancer and was a significant undertaking for a palliative care trial, namely where the emphasis was on the best, yet simplest and least toxic treatment. The research showed that radiation therapy alone is as effective in decreasing swallowing complications experienced by advanced oesophageal cancer patients as radiation therapy combined with chemotherapy, thus allowing patients to forgo chemotherapy.
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Latest News
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292